The effect of nocturnal hypoxemia on metabolic disorders in patients with stable chronic obstructive pulmonary disease
- Authors: Babak S.L.1, Gorbunova M.V.1, Malyavin A.G.1
-
Affiliations:
- Russian University of Medicine
- Issue: Vol 27, No 3 (2025): Оториноларингология и пульмонология
- Pages: 187-191
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/309760
- DOI: https://doi.org/10.26442/20751753.2025.3.203246
- ID: 309760
Cite item
Full Text
Abstract
Background. Сhronic obstructive pulmonary disease (COPD) is a heterogeneous disease with different etiologies. As lung function declines and the disease progresses, patients are at increased risk of long-term nocturnal hypoxemia (NH) with consequent tissue hypoxia. It is supposed that tissue hypoxia with NH plays a key role in a number of pathologic processes with the development of metabolic disorders.
Аim. Тo investigate the relationship between NH and metabolic disorders in stable COPD patients.
Materials and methods. A cross-sectional observational study included 106 stable COPD patients managed at a respiratory medical center between 2019 and 2024 who completed ambulatory computerized somnography, pulmonary function testing, questionnaire and laboratory screening. NH was defined according to a time to saturation under 90% (T90) index >10%. Based on the absence/presence of NH, patients were classified into groups of patients with NH (NH+) and without NH (NH-). Factors that affect NH were identified using univariate analysis and logistic regression models.
Results. The group of COPD patients with NH+ was represented by men (92.9%) with a mean age of 59.9±10.9 years, with an increased body mass index (32,14 [21.04–35.96] kg/m2); with moderate-to-severe impairment of forced expiratory volume in 1st second (FEV1) (56.19±21.17% of predicted); with decreased lung diffusing capacity for carbon monoxide (60.61±21.36% of predicted). NH+ patients compared to the NH- group had a statistically significant increase in: insulin resistance index – HOMA-IR (3.6 [3.01; 4.21] vs 2.46 [1.85; 2.88]; p<0.05); low-density lipoprotein – LDL-C (3.16 [2.83; 3.62] vs 2.49 [2.23; 2.88]; p<0.05); triglycerides (1.89 [1.70; 2.03] vs 1.58 [1.45; 1.7]; p<0.05). At the same time, high-density lipoprotein – HDL-C had a statistically significant decrease (1.00 [0.92; 1.09] vs 1.14 [1.04; 1.22]; p<0.05). Univariate regression analysis based on clinical and laboratory data showed a statistically significant association with NH for the following parameters: age (OR 1.06, 95% CI [1.02–1.12]; p=0.011), COPD Assessment Test (CAT) score (OR 1.48, 95% CI [1.10–2.00]; p=0.009), FEV1 (% of predicted) (OR 0.96, 95% CI [0.93–0.99]; p=0.015), HDL-C levels (OR 1.02, 95% CI [1.00–1.04]; p=0.034).
Conclusion. COPD patients with NH have statistically significant correlations of metabolic disorders with NH that has effect on clinical characteristics and functional disturbances. The established correlations are useful to take into consideration in current algorithms of therapy of stable COPD patients.
Full Text
##article.viewOnOriginalSite##About the authors
Sergey L. Babak
Russian University of Medicine
Author for correspondence.
Email: sergbabak@mail.ru
ORCID iD: 0000-0002-6571-1220
SPIN-code: 5213-3620
D. Sci. (Med.), Assoc. Prof.
Russian Federation, MoscowMarina V. Gorbunova
Russian University of Medicine
Email: sergbabak@mail.ru
ORCID iD: 0000-0002-2039-0072
D. Sci. (Med.)
Russian Federation, MoscowAndrey G. Malyavin
Russian University of Medicine
Email: sergbabak@mail.ru
ORCID iD: 0000-0002-6128-5914
D. Sci. (Med.)
Russian Federation, MoscowReferences
- Yan X, Song Y, Shen C, et al. Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians. Int J Chron Obstruct Pulmon Dis. 2017;12:803-12. doi: 10.2147/COPD.S114423
- Vogelmeier CF, Román-Rodríguez M, Singh D, et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi: 10.1016/j.rmed.2020.105938
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859-922. doi: 10.1016/S0140-6736(18)32335-3
- Global strategy for prevention, diagnosis and management of COPD: 2025 Report. Available at: https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf. Accessed: 26.02.2025.
- Клинические рекомендации. Хроническая обструктивная болезнь легких. 2024–2026 (17.12.2024). ID:603_3. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/603_3. Дата обращения: 26.02.2025 [Clinical guidelines. Chronic obstructive pulmonary disease. 2024–2026 (12/17/2024). ID:603_3. Available at: https://cr.minzdrav.gov.ru/view-cr/603_3 Accessed: 26.02.2025 (in Russian)].
- Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. doi: 10.5664/jcsm.6506
- Pillar G, Berall M, Berry R, et al. Detecting central sleep apnea in adult patients using WatchPAT – a multicenter validation study. Sleep Breath. 2020;24(1):387-98. doi: 10.1007/s11325-019-01904-5
- Viglino D, Martin M, Piché ME, et al. Metabolic profiles among COPD and controls in the CanCOLD population-based cohort. PLoS One. 2020;15(4):e0231072. doi: 10.1371/journal.pone.0231072
- Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199-208. doi: 10.2147/COPD.S10611
- Müllerová H, Marshall J, de Nigris E, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022;16:17534666221113647. doi: 10.1177/17534666221113647
Supplementary files
